Remdesivir reduces COVID-19 hospitalisation or death by 84%

Findings challenge the drug’s controversial past

This content has been independently produced by ADG, made possible through sponsorship from Gilead.

Real-world evidence on the effectiveness of remdesivir shows it significantly reduces hospitalisation or death from COVID-19 by 84% in high-risk patients.

The findings from a prospective cohort study challenge the drug’s controversial past and support results from an earlier randomised-controlled trial published in the New England Journal of Medicine that treatment with remdesivir (Veklury), administered intravenously in patients with an increased risk of progression, avoids hospitalisation and death.